Histone Methyltransferase
Histone modifications play critical roles in regulating both global and stage-specific gene expression. Methylation on histones H3K4, H3K36 and H3K79 is generally associated with gene activation, whereas methylation on histones H3K9 and H3K27 is generally associated with gene repression. Histone lysine methylation is dynamically regulated by site-specific methyltransferases and demethylases. EZH2 (the catalytic subunit of PRC2) is responsible for the methylation of H3K27 in cells.
DOT1L is a histone H3 lysine 79 methyltransferase whose inhibition increases the yield of induced pluripotent stem cells (iPSCs). EPZ-5676 is a potent and selective DOT1L inhibitor.
Crucial to PRC2 activity, the histone methyltransferase enhancer of zeste homolog 2 (EZH2) tri-methylates lysine 27 of histone 3 (H3K27me3), leading to chromatin condensation and transcriptional repression.
Histone Methyltransferase Isoform Specific Products
-
Histone Methyltransferase
(368)
View all products
-
EZH1
(11)
View all products
-
EZH2
(85)
View all products
-
DOT1L
(21)
View all products
-
SMYD2
(9)
View all products
-
SMYD3
(9)
View all products
-
SUV39H2/
KMT1B (4)View all products
-
EHMT2/
G9a/ (32)KMT1C View all products
-
EHMT1/
GLP/ (20)KMT1D View all products
-
ASH1L/
KMT2H (4)View all products
-
SETDB1/
KMT2G (4)View all products
-
SETD2/
KMT3A (5)View all products
-
NSD2/
MMSET/ (16)WHSC1 View all products
-
NSD3/
WHSC1L1 (4)View all products
-
SETD7/
KMT7 (6)View all products
-
SETD8/
KMT5A (5)View all products
-
PRMT1
(25)
View all products
-
PRMT3
(17)
View all products
-
PRMT4
(19)
View all products
-
PRMT5
(64)
View all products
-
PRMT6
(23)
View all products
-
PRMT7
(8)
View all products
-
PRMT8
(13)
View all products
All Product Categories
-
Histone Methyltransferase Inhibitors
(517)
View all products
-
Histone Methyltransferase Agonists
(5)
View all products
-
Histone Methyltransferase Antagonists
(11)
View all products
-
Histone Methyltransferase Activators
(5)
View all products
-
Histone Methyltransferase Modulators
(4)
View all products
-
Histone Methyltransferase Chemical
(1)
View all products
-
Histone Methyltransferase Inducers
(3)
View all products
-
Histone Methyltransferase Degraders
(68)
View all products
-
Histone Methyltransferase Controls
(8)
View all products
-
Histone Methyltransferase Ligands
(16)
View all products
-
Histone Methyltransferase Related Products (687)
Related Products (687)
-
Antibodies (84)
-
Histone Methyltransferase Isoform Comparison
-
EEDi-5285
0 ImagesEEDi-5285 is an exceptionally potent and orally active embryonic ectoderm development (EED) inhibitor with an IC50 value of 0.2 nM for binds to the EED protein. EEDi-5285 has anti-cancer activity.
-
CM-579 trihydrochloride
0 ImagesCat. No.: HY-117421ACAS No.: 2448471-08-5CM-579 trihydrochloride is a first-in-class reversible, dual inhibitor of G9a and DNMT, with IC50 values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells.
-
EM127
0 ImagesEM127 (compound 11c) is a SMYD3 covalent inhibitor with high selectivity, high affinity (KD=13 μM) and site-specificity. EM127 effectively inhibits ERK1/2 phosphorylation and reduces transcriptional regulation of SMYD3 target genes. EM127 effectively and prolongedly impairs methyltransferase activity. EM127 can be used in cancer research, particularly in SMYD3 positive tumours.
-
SPEN-IN-1
0 ImagesCat. No.: HY-152038CAS No.: 2863686-82-0SPEN-IN-1 (compound X1) is an inhibitor of SPEN which is a protein factor with a Kd value of 47 nM. SPEN-IN-1 has high selectivity for RepA, a 431-nucleotide domain in Xist (a non-coding RNA prototype) that comprises 8.5 units of a GC-rich motif responsible for gene silencing.
-
NV03
0 ImagesNV03 is a potent and selective antagonist of Ubiquitin-like with PHD and RING finger domains 1 (UHRF1)-H3K9me3 interaction by binding to UHRF1 tandem tudor domain, with a Kd of 2.4 μM. NV03 is also a ligand for E3 ligase. NV03 can be studied in anticancer research.
-
W4275
0 ImagesW4275 (Compound 42) is a selective NSD2 inhibitor with oral activity, showing an IC50 value of 17 nM. W4275 exhibits antiproliferative activity with an IC50 of 230 nM against RS411 cells and significantly inhibits tumor growth in the RS411 tumor xenograft model. Pharmacokinetic analysis in mice demonstrates that W4275 has good oral bioavailability (F of 27.34%). W4275 holds promise for use in cancer research.
-
OTS193320
0 ImagesOTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX.
-
Tazemetostat (Standard)
0 ImagesSynonyms: EPZ-6438 (Standard); E-7438 (Standard)Tazemetostat (Standard) is the analytical standard of Tazemetostat. This product is intended for research and analytical applications. Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 of 4 nM. Tazemetostat also inhibits EZH1 with an IC50 of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells.
-
BIX-01294 trihydrochloride
0 ImagesBIX-01294 trihydrochloride is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC50s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 trihydrochloride inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294 trihydrochloride, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 trihydrochloride has antitumor activity in recurrent tumor cells.
-
ZLD1039
0 ImagesZLD1039 is a potent, highly selective, and orally bioavailable EZH2 inhibitor. ZLD1039 shows potent and concentration-dependent inhibition of PRC2 enzymatic activity against EZH2 wild-type as well as Y641F, and A677G mutant enzymes with IC50 values of 5.6, 15, and 4.0 nM, respectively. ZLD1039 inhibits breast tumor growth and metastasis.
-
MS147
0 ImagesCat. No.: HY-160924Purity: 98.31%MS147 is a VHL-based PROTAC degrader of BMI1 and RING1B (polycomb repressive complex 1 core components). MS147 directly binds EED and VHL E3 ligase, recruiting the ligase to the EED-BMI1/RING1B complex to induce time-dependent, ubiquitination-mediated degradation of BMI1 and RING1B. MS147 reduces histone H2A Lys119 mono-ubiquitination without altering histone H3 Lys27 tri-methylation and inhibits cancer cells proliferation. MS147 can be used for the research of cancer, such as chronic myelogenous leukemia and b-cell lymphoma.
-
UNC10013
0 ImagesCat. No.: HY-173156Purity: 99.71%UNC10013 is an inhibitor targeting the triple Tudor domain (3TD) of SETDB1. UNC10013 covalently binds to Cys385 of SETDB1 3TD, acts as a negative allosteric modulator of the methyltransferase domain of SETDB1, reduces the level of Akt methylation mediated by SETDB1, and blocks Tyr308 phosphorylation of Akt. UNC10013 is applicable to cancer-related research.
